PMID- 29277813
OWN - NLM
STAT- MEDLINE
DCOM- 20180104
LR  - 20180104
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Clinical Trial of Radiotherapy After Intravenous Injection of Acridine Orange for 
      Patients with Cancer.
PG  - 481-489
AB  - AIM: We previously found that low-dose X-ray treatment after systemic 
      administration of acridine orange (AO), which is known to have a low toxicity in 
      animals, inhibited tumor growth in experimental studies using mouse osteosarcoma. 
      In this pilot study, we planned to verify the toxicity of intravenous injection 
      of low-dose AO in humans and investigate the anticancer effect of radiation after 
      systemic AO administration (iAOR) for human cancer. PATIENTS AND METHODS: Eight 
      patients with terminal cancer were treated with iAOR. RESULTS: None of the 
      patients exhibited an adverse effect from AO injection. Three out of the five 
      patients who received a full course of iAOR exhibited clinical or image-based 
      responses, whereas two patients did not. CONCLUSION: The systemic administration 
      of AO was confirmed not to be toxic in humans, and iAOR was suggested to be 
      potentially effective against radioresistant cancer.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kusuzaki, Katsuyuki
AU  - Kusuzaki K
AD  - Department of Musculoskeletal Oncology, Tenri, Japan 18kusu43@gmail.com.
FAU - Takai, Tetsuo
AU  - Takai T
AD  - Department of Orthopaedic Surgery, Tenri, Japan.
FAU - Yoshimura, Hitoshi
AU  - Yoshimura H
AD  - Department of Radiology, Tenri, Japan.
FAU - Inoue, Kazuya
AU  - Inoue K
AD  - Department of Radiology, Tenri, Japan.
FAU - Takai, Shigeo
AU  - Takai S
AD  - Department of General Medicine of Takai Hospital, Tenri, Japan.
FAU - Baldini, Nicola
AU  - Baldini N
AD  - Laboratory for Orthopaedic Pathophysiology and Regenerative Medicine, Rizzoli 
      Orthopaedic Institute, Bologna, Italy.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Mutagens)
RN  - F30N4O6XVV (Acridine Orange)
SB  - IM
MH  - Acridine Orange/*therapeutic use/*toxicity
MH  - Humans
MH  - Mutagens/*therapeutic use/toxicity
MH  - Neoplasms/*drug therapy/*radiotherapy
MH  - Pilot Projects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Acridine orange
OT  - autophagy
OT  - cancer
OT  - radiotherapy
OT  - toxicity
EDAT- 2017/12/27 06:00
MHDA- 2018/01/05 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/13 00:00 [received]
PHST- 2017/11/02 00:00 [revised]
PHST- 2017/11/13 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
AID - 38/1/481 [pii]
AID - 10.21873/anticanres.12248 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):481-489. doi: 10.21873/anticanres.12248.